Alireza Monshizadeh MANUCHEHRI,Klaus Andreas DUGI,Peter EICKELMANN,Leo THOMAS
申请号：
US15465680
公开号：
US20170189437A1
申请日:
2017.03.22
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention is directed to a pharmaceutical composition comprised of one or more SGLT-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class I obesity, class II obesity, class III obesity, visceral obesity and abdominal obesity, and metabolic syndrome.
